Effectiveness of Monovalent mRNA COVID-19 Vaccination in Preventing COVID-19-Associated Invasive Mechanical Ventilation and Death Among Immunocompetent Adults During the Omicron Variant Period - IVY Network, 19 U.S. States, February 1, 2022-January 31, 2023

• Published in: MMWR. Morbidity and mortality weekly report 2023-04, Vol.72 (17), p.463-468
• Main Authors: DeCuir, Jennifer, Surie, Diya, Zhu, Yuwei, Gaglani, Manjusha, Ginde, Adit A, Douin, David J, Talbot, H Keipp, Casey, Jonathan D, Mohr, Nicholas M, McNeal, Tresa, Ghamande, Shekhar, Gibbs, Kevin W, Files, D Clark, Hager, David N, Phan, Minh, Prekker, Matthew E, Gong, Michelle N, Mohamed, Amira, Johnson, Nicholas J, Steingrub, Jay S, Peltan, Ithan D, Brown, Samuel M, Martin, Emily T, Monto, Arnold S, Khan, Akram, Bender, William S, Duggal, Abhijit, Wilson, Jennifer G, Qadir, Nida, Chang, Steven Y, Mallow, Christopher, Kwon, Jennie H, Exline, Matthew C, Lauring, Adam S, Shapiro, Nathan I, Columbus, Cristie, Gottlieb, Robert, Vaughn, Ivana A, Ramesh, Mayur, Lamerato, Lois E, Safdar, Basmah, Halasa, Natasha, Chappell, James D, Grijalva, Carlos G, Baughman, Adrienne, Womack, Kelsey N, Rhoads, Jillian P, Hart, Kimberly W, Swan, Sydney A, Lewis, Nathaniel, McMorrow, Meredith L, Self, Wesley H
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Adults; Analysis; COVID-19 - prevention & control; COVID-19 Vaccines; Hospital Mortality; Humans; Messenger RNA; Pandemics; Respiration, Artificial; RNA, Messenger; SARS-CoV-2; Vaccination
• ISSN: 0149-2195; 1545-861X
• DOI: 10.15585/mmwr.mm7217a3

As of April 2023, the COVID-19 pandemic has resulted in 1.1 million deaths in the United States, with approximately 75% of deaths occurring among adults aged ≥65 years (1). Data on the durability of protection provided by monovalent mRNA COVID-19 vaccination against critical outcomes of COVID-19 are limited beyond the Omicron BA.1 lineage period (December 26, 2021-March 26, 2022). In this case-control analysis, the effectiveness of 2-4 monovalent mRNA COVID-19 vaccine doses was evaluated against COVID-19-associated invasive mechanical ventilation (IMV) and in-hospital death among immunocompetent adults aged ≥18 years during February 1, 2022-January 31, 2023. Vaccine effectiveness (VE) against IMV and in-hospital death was 62% among adults aged ≥18 years and 69% among those aged ≥65 years. When stratified by time since last dose, VE was 76% at 7-179 days, 54% at 180-364 days, and 56% at ≥365 days. Monovalent mRNA COVID-19 vaccination provided substantial, durable protection against IMV and in-hospital death among adults during the Omicron variant period. All adults should remain up to date with recommended COVID-19 vaccination to prevent critical COVID-19-associated outcomes.